Physician profile
Robert Pickerill
NPI 1710971882
$5,797.14
in general payments reported to CMS, 2019-2025
20 companies · $276 in 2025
The $276 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,016 · 2020: $668 · 2021: $963 · 2022: $704 · 2023: $260 · 2024: $910 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,446.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,508.28 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,218.53 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $599.95 | 2019-2021 | |
| Grifols USA, LLC | $455.29 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $430.31 | 2019-2024 | Dupixent |
| Pfizer INC. | $212.66 | 2019-2020 | |
| Allergan, INC. | $207.30 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.95 | 2019-2020 | |
| Stryker Corporation | $151.06 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Genzyme Corporation | $125.00 | 2021 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2024 | Opsumit, Uptravi |
| Amgen INC. | $105.46 | 2019 | |
| Janssen Pharmaceuticals, INC | $92.14 | 2019 | |
| Abbvie INC. | $85.95 | 2021-2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $58.32 | 2019 | |
| Sanofi-Aventis U.S. LLC | $47.56 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.55 | 2021 | |
| Vifor Pharma, INC. | $23.38 | 2024 | Zemaira |
| Insmed, INC. | $22.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Pickerill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.